Clinical Trial

Research for Resistance Factors in the Treatment of Lymphoid Hemopathy

Study acronym: REFRACT-LyMA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
In order to promote translational research on the molecular pathways involved in resistance to treatments for mantle cell lymphoma (MCL), the clinical haematology department of the University Hospital Center (CHU) of Nantes has established, since 2016, the REFRACT-LyMa (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mantle Cell Lymphoma) cohort-biocollection of blood and bone marrow samples from patients with MCL. Thanks to the close collaborations with team 11 of the Integrated Cancer Research and Immunology Center Nantes Angers (CRCI²NA), which specializes in studying the molecular pathways involved in resistance to treatments for hematological cancers, we wish to broaden the scope of research to other B-cell non-Hodgkin lymphomas (B-NHL). That is why today the REFRACT-LyMa cohort-biocollection aims to expand to malignant hematopathies involving mature B cells (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mature B-Cell Lymphoid Hemopathies).
Protocol Amendment History 3 changes
notable Trial sites expanded: 1 -> 4 locations 2026-06-13
notable Primary completion pushed: 2026-03-01 -> 2036-06-01 2026-05-30
minor Completion pushed: 2026-03-01 -> 2036-06-01 2026-05-30
Trial Details
NCT Number NCT07385612
Lead Sponsor Nantes University Hospital
Conditions MATURE B-CELL LYMPHOIDS
Enrollment 80 participants
Start Date 2026-06-01
Primary Completion 2036-06-01 (estimated)
Study Completion 2036-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12